This Event Ran on March 2022

8:55 am Chair’s Opening Remarks

• Jessica Shore Vice President -Research and Programs, Pulmonary Fibrosis Foundation

Uncovering the Clinical Research Propelling ILD Drug Development Forwards in 2022 & Beyond

9:00 am Strategically Leveraging ILD Clinical Trials to Further Our Understanding of The Progressive Pulmonary Fibrosis Phenotype & Identify Novel Outcomes in Clinical Trials

• Craig Conoscenti Medical Expert ILD Respiratory Clinical Development & Medical Affairs, Boehringer Ingelheim

9:30 am Looking Beyond IPF: Utilizing Lessons Learned from IPF Clinical Trials to Inform & Optimize Your ILD Trial Design & Execution

• Eric White Senior Clinical Program Lead, Boehringer Ingelheim

10:00 am Panel Discussion: Bringing the Patient Voice into Clinical Trial Design and Conduct

• Steve Jones President, EUIPFF
• Sharon Lee Executive Director, Canadian Pulmonary Fibrosis Foundation
• Sabine Pinnetti Clinical Development & Operations Lead, Boehringer Ingelheim
• Annie Gilbert Clinical Development & Operations Patient & Site Engagement Lead, Boehringer Ingelheim

10:30 am Speed Networking

11:00 am Morning Break

Uncovering Emerging ILD Therapeutic Approaches

11:30 am Developing Therapies for Rare Lung Diseases: ILD 101

• Rohit Batta Chief Medical Officer, Vicore Pharma

12:00 pm Single vs Multiple Benefit Drugs for ILD

• Matt Bradley CEO, Chairman & Founder, SAJE Pharma

12:30 pm Lunch Break & Networking

1:30 pm Update on Inhaled Drug Delivery: The Application of Anticalins in the Treatment of Lung Fibrosis

• Vanessa Neins Senior Scientist - Biology Lead Respiratory, Pieris Pharmaceuticals

Analyzing & Scrutinizing ILD Mechanisms

2:00 pm Evolution of Multicellular Hubs in the Tumor Microenvironment & their Relevance for ILD Drug Development

• Shannon Turley Vice President of Cancer Immunology Discovery, Genentech

2:30 pm The Role of Macrophage Metabolic Reprogramming During Pulmonary Fibrosis

• Adam Byrne Professor, Imperial College London

3:00 pm Afternoon Break & Networking

Strategizing New Target Identification for Novel Therapies 101

3:30 pm Selective Inhibition of ROCK2: Promising Approach to Target Fibrosis

• Nicolas Guisot Research Fellow & Project Leader, Redx Pharma

4:00 pm Revealing What Steps You Must Take to Successfully Identify & Validate Novel ILD Therapeutic Targets which Target Lung Epithelial injury

• Glenn Rosen Chief Scientific Officer, Optikira & Biomotiv

4:30 pm How Three Lakes Foundation is Catalyzing Efforts to Benefit Patients With ILD and Pulmonary Fibrosis

• Cheryl Nutter Senior Vice President Research & Development, Three Lakes Foundation

5:00 pm Chair’s Closing Remarks